ID

19138

Description

Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies; ODM derived from: https://clinicaltrials.gov/show/NCT00492466

Link

https://clinicaltrials.gov/show/NCT00492466

Keywords

  1. 12/7/16 12/7/16 -
Uploaded on

December 7, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Relapsing-Remitting Multiple Sclerosis NCT00492466

Eligibility Relapsing-Remitting Multiple Sclerosis NCT00492466

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
relapsing remitting multiple sclerosis according to poser criteria (cdms or ldms) or multiple sclerosis according to mcdonald criteria
Description

Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis

Data type

boolean

Alias
UMLS CUI [1]
C0751967
UMLS CUI [2]
C0026769
disability equivalent to edss of 6.0 or less
Description

EDSS

Data type

boolean

Alias
UMLS CUI [1]
C0451246
clinical activity defined as at least one relapse rate within the last 12 months
Description

Relapse Quantity

Data type

boolean

Alias
UMLS CUI [1,1]
C0277556
UMLS CUI [1,2]
C1265611
nab titre >20 (measured at least 48 hours after last interferon-beta injection
Description

Neutralizing Antibody titer measurement | Interferon-beta Injection

Data type

boolean

Alias
UMLS CUI [1,1]
C0475463
UMLS CUI [1,2]
C0474643
UMLS CUI [2,1]
C0015980
UMLS CUI [2,2]
C1828121
has been treated with subcutaneously administered interferon-beta-1b or interferon-beta-1a (rebif) for at least 24 hours before enrollment
Description

interferon beta-1b Subcutaneous | Interferon beta-1a Subcutaneous | Rebif Subcutaneous

Data type

boolean

Alias
UMLS CUI [1,1]
C0244713
UMLS CUI [1,2]
C1522438
UMLS CUI [2,1]
C0254119
UMLS CUI [2,2]
C1522438
UMLS CUI [3,1]
C0752980
UMLS CUI [3,2]
C1522438
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
any condition that might give rise to similar symptoms as ms
Description

Condition Causing Symptoms Multiple Sclerosis Similar

Data type

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C0678227
UMLS CUI [1,3]
C1457887
UMLS CUI [1,4]
C0026769
UMLS CUI [1,5]
C2348205
immunomodulatory therapy other than interferon-beta-1a or interferon-beta-1b or any immunosuppressive treatment six months prior to inclusion into the trial
Description

Immunomodulation | Interferon beta-1a | interferon beta-1b | Therapeutic immunosuppression

Data type

boolean

Alias
UMLS CUI [1]
C1963758
UMLS CUI [2]
C0254119
UMLS CUI [3]
C0244713
UMLS CUI [4]
C0021079
treatment with glucocorticoids or acth less than one month prior to inclusion into the trial
Description

Glucocorticoids | Corticotropin

Data type

boolean

Alias
UMLS CUI [1]
C0017710
UMLS CUI [2]
C0001655
history of major depression
Description

Major Depressive Disorder

Data type

boolean

Alias
UMLS CUI [1]
C1269683
alcohol or drug dependency
Description

Substance Dependence

Data type

boolean

Alias
UMLS CUI [1]
C0038580
cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable or advanced ischemic heart disease (nyha iii or iv)
Description

Heart failure | Cardiomyopathy | Cardiac Arrhythmia Significant | Myocardial Ischemia Unstable New York Heart Association Classification | Myocardial Ischemia Advanced New York Heart Association Classification

Data type

boolean

Alias
UMLS CUI [1]
C0018801
UMLS CUI [2]
C0878544
UMLS CUI [3,1]
C0003811
UMLS CUI [3,2]
C0750502
UMLS CUI [4,1]
C0151744
UMLS CUI [4,2]
C0443343
UMLS CUI [4,3]
C1275491
UMLS CUI [5,1]
C0151744
UMLS CUI [5,2]
C0205179
UMLS CUI [5,3]
C1275491
hypertension (bp > 180/110 mmhg)
Description

Hypertensive disease | Blood Pressure

Data type

boolean

Alias
UMLS CUI [1]
C0020538
UMLS CUI [2]
C0005823
renal insufficiency defined as serum creatinine > 1.5 times the upper normal reference limit
Description

Renal Insufficiency | Creatinine measurement, serum

Data type

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C0201976
any systemic disease that can influence the patient's safety and compliance, or the evaluation of the disability
Description

Systemic disease Affecting patient safety | Systemic disease Limiting Compliance behavior | Systemic disease Affecting Evaluation Disability

Data type

boolean

Alias
UMLS CUI [1,1]
C0442893
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C1113679
UMLS CUI [2,1]
C0442893
UMLS CUI [2,2]
C0439801
UMLS CUI [2,3]
C1321605
UMLS CUI [3,1]
C0442893
UMLS CUI [3,2]
C0392760
UMLS CUI [3,3]
C1261322
UMLS CUI [3,4]
C0231170
gastro-intestinal ulcers, gastritis, or dyspepsia
Description

Gastrointestinal ulcer | Gastritis | Dyspepsia

Data type

boolean

Alias
UMLS CUI [1]
C0237938
UMLS CUI [2]
C0017152
UMLS CUI [3]
C0013395
women who are pregnant, breast-feeding or have the possibility for pregnancy during the trial. to avoid pregnancy, women have to be postmenopausal, surgical sterile, sexually inactive or practice reliable contraceptives
Description

Pregnancy | Breast Feeding | Pregnancy Possible | Postmenopausal state | Female Sterilization | Sexual Abstinence | Contraceptive methods

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C0032961
UMLS CUI [3,2]
C0332149
UMLS CUI [4]
C0232970
UMLS CUI [5]
C0015787
UMLS CUI [6]
C0036899
UMLS CUI [7]
C0700589

Similar models

Eligibility Relapsing-Remitting Multiple Sclerosis NCT00492466

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis
Item
relapsing remitting multiple sclerosis according to poser criteria (cdms or ldms) or multiple sclerosis according to mcdonald criteria
boolean
C0751967 (UMLS CUI [1])
C0026769 (UMLS CUI [2])
EDSS
Item
disability equivalent to edss of 6.0 or less
boolean
C0451246 (UMLS CUI [1])
Relapse Quantity
Item
clinical activity defined as at least one relapse rate within the last 12 months
boolean
C0277556 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Neutralizing Antibody titer measurement | Interferon-beta Injection
Item
nab titre >20 (measured at least 48 hours after last interferon-beta injection
boolean
C0475463 (UMLS CUI [1,1])
C0474643 (UMLS CUI [1,2])
C0015980 (UMLS CUI [2,1])
C1828121 (UMLS CUI [2,2])
interferon beta-1b Subcutaneous | Interferon beta-1a Subcutaneous | Rebif Subcutaneous
Item
has been treated with subcutaneously administered interferon-beta-1b or interferon-beta-1a (rebif) for at least 24 hours before enrollment
boolean
C0244713 (UMLS CUI [1,1])
C1522438 (UMLS CUI [1,2])
C0254119 (UMLS CUI [2,1])
C1522438 (UMLS CUI [2,2])
C0752980 (UMLS CUI [3,1])
C1522438 (UMLS CUI [3,2])
Item Group
C0680251 (UMLS CUI)
Condition Causing Symptoms Multiple Sclerosis Similar
Item
any condition that might give rise to similar symptoms as ms
boolean
C0348080 (UMLS CUI [1,1])
C0678227 (UMLS CUI [1,2])
C1457887 (UMLS CUI [1,3])
C0026769 (UMLS CUI [1,4])
C2348205 (UMLS CUI [1,5])
Immunomodulation | Interferon beta-1a | interferon beta-1b | Therapeutic immunosuppression
Item
immunomodulatory therapy other than interferon-beta-1a or interferon-beta-1b or any immunosuppressive treatment six months prior to inclusion into the trial
boolean
C1963758 (UMLS CUI [1])
C0254119 (UMLS CUI [2])
C0244713 (UMLS CUI [3])
C0021079 (UMLS CUI [4])
Glucocorticoids | Corticotropin
Item
treatment with glucocorticoids or acth less than one month prior to inclusion into the trial
boolean
C0017710 (UMLS CUI [1])
C0001655 (UMLS CUI [2])
Major Depressive Disorder
Item
history of major depression
boolean
C1269683 (UMLS CUI [1])
Substance Dependence
Item
alcohol or drug dependency
boolean
C0038580 (UMLS CUI [1])
Heart failure | Cardiomyopathy | Cardiac Arrhythmia Significant | Myocardial Ischemia Unstable New York Heart Association Classification | Myocardial Ischemia Advanced New York Heart Association Classification
Item
cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable or advanced ischemic heart disease (nyha iii or iv)
boolean
C0018801 (UMLS CUI [1])
C0878544 (UMLS CUI [2])
C0003811 (UMLS CUI [3,1])
C0750502 (UMLS CUI [3,2])
C0151744 (UMLS CUI [4,1])
C0443343 (UMLS CUI [4,2])
C1275491 (UMLS CUI [4,3])
C0151744 (UMLS CUI [5,1])
C0205179 (UMLS CUI [5,2])
C1275491 (UMLS CUI [5,3])
Hypertensive disease | Blood Pressure
Item
hypertension (bp > 180/110 mmhg)
boolean
C0020538 (UMLS CUI [1])
C0005823 (UMLS CUI [2])
Renal Insufficiency | Creatinine measurement, serum
Item
renal insufficiency defined as serum creatinine > 1.5 times the upper normal reference limit
boolean
C1565489 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
Systemic disease Affecting patient safety | Systemic disease Limiting Compliance behavior | Systemic disease Affecting Evaluation Disability
Item
any systemic disease that can influence the patient's safety and compliance, or the evaluation of the disability
boolean
C0442893 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C1113679 (UMLS CUI [1,3])
C0442893 (UMLS CUI [2,1])
C0439801 (UMLS CUI [2,2])
C1321605 (UMLS CUI [2,3])
C0442893 (UMLS CUI [3,1])
C0392760 (UMLS CUI [3,2])
C1261322 (UMLS CUI [3,3])
C0231170 (UMLS CUI [3,4])
Gastrointestinal ulcer | Gastritis | Dyspepsia
Item
gastro-intestinal ulcers, gastritis, or dyspepsia
boolean
C0237938 (UMLS CUI [1])
C0017152 (UMLS CUI [2])
C0013395 (UMLS CUI [3])
Pregnancy | Breast Feeding | Pregnancy Possible | Postmenopausal state | Female Sterilization | Sexual Abstinence | Contraceptive methods
Item
women who are pregnant, breast-feeding or have the possibility for pregnancy during the trial. to avoid pregnancy, women have to be postmenopausal, surgical sterile, sexually inactive or practice reliable contraceptives
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0032961 (UMLS CUI [3,1])
C0332149 (UMLS CUI [3,2])
C0232970 (UMLS CUI [4])
C0015787 (UMLS CUI [5])
C0036899 (UMLS CUI [6])
C0700589 (UMLS CUI [7])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial